TABLE 3.
Results
| Follow-up at 15±7 months | |||
|---|---|---|---|
| Tacrolimus/prednisone | Tacrolimus/prednisone/MMF | Overall | |
| 1-year actuarial patient survival (whole group) | 93% | 96% | 94% |
| 1-year actuarial patient survival (stratified group) | 95% | 98% | 97% |
| 1-year actuarial graft survival (whole group) | 85% | 89% | 87% |
| 1-year actuarial graft survival (stratified group) | 92% | 93% | 93% |
| Rejection | 44% | 27%a | 36% |
| Steroid-resistant rejection | 7.5% | 2.9% | 5.3% |
| Serum creatinine (mg/dl) | 1.6±0.9 | 1.7±0.7 | 1.6±0.8 |
| Tacrolimus dose (mg/day) | 8.4±6.0 | 9.0±7.1 | 8.7±6.6 |
| Tacrolimus level (ng/ml) | 10.2±4.5 | 10.1±4.2 | 10.1±4.4 |
| Off steroids | 34% | 39% | 36% |
| Off antihypertensive medications | 25% | 39% | 32% |
| Cholesterol (mg/dl) | 200±62 | 192±46 | 196±55 |
| Cytomegalovirus | 8.5% | 16.7% | 12.5% |
| Posttransplant lymphoproliferative disorder | 0.9% | 0% | 0.5% |
| Delayed graft function | 21% | 21% | 21% |
| PTDM | |||
| Initial | 9.3% | 4.7% | 7.0% |
| Final | 4.7% | 1.2% | 2.9% |
| Cross-over | 2→3 | 3→2 | |
| 28% | 34% (2nd year; 12%) | 31% | |
a
p = 0.014.